#Coronavirus Disease Research #References (AMEDEO, June 13 '26)

 

Clin Infect Dis

1. BRITT NS, Khader K, He T, Prinzi AM, et al
   Clinical Impact of the BIOFIRE(R) FILMARRAY(R) Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study.
   Clin Infect Dis. 2026 Jun 12:ciag328. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

2. NERBY J, Berg W, McFarren M, Rhame F, et al
   Collaborative approaches to masking: statewide threshold development and performance across three respiratory seasons.
   Infect Control Hosp Epidemiol. 2026 Jun 11:1-7. doi: 10.1017/ice.2026.10487.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. CHEN H, Manu EK
   Shifting patterns of acute respiratory infection mortality in Australia: Changing contributions of COVID-19, influenza and respiratory syncytial virus and persistent Indigenous inequalities.
   Int J Infect Dis. 2026 Jun 8:108866. doi: 10.1016/j.ijid.2026.108866.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

4. MEYBOHM P, Baron DM, Fries D, Lasocki S, et al
   Patient blood management in general intensive care patients.
   Intensive Care Med. 2026 Jun 8. doi: 10.1007/s00134-026-08491.
   PubMed         Abstract available
   
   

   
   J Infect

5. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
   Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
   J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
   PubMed         Abstract available
   
   
6. WANG X, Yin J, Xu B, Guanhua X, et al
   Clinical epidemiological characteristics of hospitalized pediatric Mycoplasma pneumoniae pneumonia in China.
   J Infect. 2026 Jun 10:106793. doi: 10.1016/j.jinf.2026.106793.
   PubMed         Abstract available
   
   
7. TRUONG T, Radin JM, Li L, Ordonez-Mena JM, et al
   Burden and economic impact of RSV hospitalisations among English adults, 2023/24.
   J Infect. 2026;93:106792.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. USHIJIMA H, Onda-Shimizu Y, Kotaki T, Nishimura S, et al
   Co-Circulation and Mixed Infections of Classic and Melbourne Human Astroviruses Among Pediatric Acute Gastroenteritis Patients in Japan, 2018-2024.
   J Med Virol. 2026;98:e71002.
   PubMed         Abstract available
   
   
9. AYDIN U, Duzenci D, Akkoc RF, Karatas A, et al
   Serum Histatin Levels in COVID-19: Association With Disease Severity and Immune Status.
   J Med Virol. 2026;98:e71009.
   PubMed         Abstract available
   
   
10. CHEN R, Kong W, Li C, Zhang J, et al
    TXD-198 Exhibits Inhibitory Activity Against SARS-CoV-2 by Upregulating ANO1.
    J Med Virol. 2026;98:e71004.
    PubMed         Abstract available
    
    
11. DENG J, Lin Q, Zeng Z, Huang H, et al
    Post-Pandemic Influenza Resurgence in Guangzhou, China: Impact of COVID-19 Interventions and Immune Alterations.
    J Med Virol. 2026;98:e71012.
    PubMed         Abstract available
    
    
12. FU JYL, Lim SK, Jalalonmuhali M, Bador MK, et al
    Immune Pressure From Plasma From Immunocompromised and Healthy Individuals Drives Differential SARS-CoV-2 Evolution and Escape Mutation Emergence.
    J Med Virol. 2026;98:e71016.
    PubMed         Abstract available
    
    

    
    J Travel Med

13. LUBBERT C, Fruhwein M, Dinjer CS, Machler C, et al
    Assessment of the healthcare burden of dengue disease in Germany: a retrospective analysis of statutory health insurance data (2014-2023).
    J Travel Med. 2026 Jun 11:taag047. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

14. YANG Y, Su Z, Zhang X, Tan Y, et al
    PPP2R5B regulates ANPEP expression and TGEV entry via dephosphorylation of HSF1 at Ser304/Ser308.
    J Virol. 2026 Jun 11:e0016626. doi: 10.1128/jvi.00166.
    PubMed         Abstract available
    
    
15. YO MS, Kaku Y, Kosugi Y, Tolentino JE, et al
    Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.
    J Virol. 2026 Jun 10:e0035226. doi: 10.1128/jvi.00352.
    PubMed         Abstract available
    
    
16. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available
    
    
17. ARTUSA V, Limanaqi F, Santacroce E, Clerici M, et al
    Alpha-synuclein at the crossroads of host-virus interactions: immunological roles beyond the nervous system.
    J Virol. 2026 Jun 9:e0019126. doi: 10.1128/jvi.00191.
    PubMed         Abstract available
    
    
18. VARGAS DA, Albornoz LL, Pena-Morales M, Ortiz Rojas HJ, et al
    Within-host SARS-CoV-2 diversity in immunocompromised patients during acute infection.
    J Virol. 2026 Jun 9:e0222425. doi: 10.1128/jvi.02224.
    PubMed         Abstract available
    
    
19. YU H-M, Zhu M-L, Zhao Y-L, Tan J-X, et al
    Research progress on the association between viruses and cardiac diseases.
    J Virol. 2026 Jun 9:e0038326. doi: 10.1128/jvi.00383.
    PubMed         Abstract available
    
    
20. LI S, Luo H, Zhang K, Wu C, et al
    The cholesterol transporter Niemann-Pick C1 facilitates the entry of porcine epidemic diarrhea coronavirus.
    J Virol. 2026 Jun 9:e0030126. doi: 10.1128/jvi.00301.
    PubMed         Abstract available
    
    
21. ZHANG Q, Xin J, Wang C, Zhang X, et al
    Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.
    J Virol. 2026 Jun 12:e0043426. doi: 10.1128/jvi.00434.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

22. XIE Y, Choi T, Al-Aly Z
    Seasonal influenza versus COVID-19 hospitalisation risk during the 2025-26 influenza season.
    Lancet Infect Dis. 2026 Jun 10:S1473-3099(26)00289.
    PubMed        
    
    

    
    Travel Med Infect Dis

23. MIHAI I, Bonnaud L, Arregle F, Doudier B, et al
    Purulent meningococcal pericarditis with cardiac tamponade in a Hajj pilgrim: A diagnostic challenge of anchoring bias on MERS-CoV.
    Travel Med Infect Dis. 2026;72:103001.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 13 '26)

 

Arch Virol

1. SMATTI MK, Al-Khatib H, Suleman M, Nizar M, et al
   Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.
   Arch Virol. 2026;171:198.
   PubMed         Abstract available
   
   

   
   J Infect

2. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
   Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
   J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
   PubMed         Abstract available
   
   
3. CORRAO G, Sguazzini E, Gori A, Monti E, et al
   All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
   J Infect. 2026;93:106769.
   PubMed         Abstract available
   
   
4. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
   Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
   J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. LIU F, Gross FL, Li Z, House SL, et al
   Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness.
   J Infect Dis. 2026 Jun 8:jiag294. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

6. LIU Z, Fan M, Zeng Y, Zheng Y, et al
   Gga-miR-92-targeted TNFRSF1B inhibits the replication of influenza A virus by degrading TRAF3.
   J Virol. 2026 Jun 12:e0067426. doi: 10.1128/jvi.00674.
   PubMed         Abstract available
   
   
7. XU S, Zhang Q, Xie X, Zhou M, et al
   A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.
   J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563.
   PubMed         Abstract available
   
   
8. PENG M, Liu L, Li X, Yu X, et al
   Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
   J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

9. LIN Z, Gao Y, Sun W
   Supervised deep learning with gene functional annotation for cell classification.
   PLoS Comput Biol. 2026;22:e1014327.
   PubMed         Abstract available
   
   
10. KWON J, Li K, Warren JL, Pandya S, et al
    Utilizing virus genomic surveillance to predict vaccine effectiveness.
    PLoS Comput Biol. 2026;22:e1014329.
    PubMed         Abstract available
    
    

    
    PLoS One

11. TAM VCW, Yeung NCY, Kwok AWL
    Getting over the hurdles to save lives: Incorporating perceived barriers into theory of planned behaviour (TPB) model to predict stated intention among Hong Kong trained laymen.
    PLoS One. 2026;21:e0350392.
    PubMed         Abstract available
    
    
12. KONDO K, Morita I, Sakuma S, Ohsawa I, et al
    Changes in tobacco sales before, during, and after the COVID-19 pandemic in Japan: An interrupted time series analysis.
    PLoS One. 2026;21:e0350820.
    PubMed         Abstract available
    
    
13. WOODGATE RL, Mary-Quigley L, Bell A, Bennett M, et al
    Youth's mental health journeys through the COVID-19 pandemic using arts-based methods in virtual environments.
    PLoS One. 2026;21:e0349860.
    PubMed         Abstract available
    
    
14. KARAMI B, Rezaeian S, Bagherinia M, Shakiba E, et al
    Social support and health related quality of life among older people in covid-19 pandemic: The mediating role of resilience.
    PLoS One. 2026;21:e0342982.
    PubMed         Abstract available
    
    
15. YANG RJ, Wang M, Lyu L, You JL, et al
    Pathogen spectrum and epidemiology of respiratory tract infections in Quzhou, Eastern China, from November 2023 to July 2024: A post?COVID?19 surveillance study.
    PLoS One. 2026;21:e0346441.
    PubMed         Abstract available
    
    
16. BOLSHOV O, Chumachenko D
    Reinforcement learning for policymaking in epidemic control: A scoping review.
    PLoS One. 2026;21:e0351176.
    PubMed         Abstract available
    
    
17. LIU C, Liu H, Wei Y, Ye J, et al
    Modeling the effects of meteorological factors and media-driven public awareness on seasonal influenza outbreaks.
    PLoS One. 2026;21:e0342962.
    PubMed         Abstract available
    
    
18. LIU F, Lai T, Xu W, Li G, et al
    ViralMultiNet: A structure-aware multimodal framework for viral protein function prediction in wastewater surveillance.
    PLoS One. 2026;21:e0349393.
    PubMed         Abstract available
    
    
19. MOUNCHID PM, Shukla S, Steinert JI
    The interplay of economic shocks and cultural practices in child marriage: Comparative evidence from India and Zambia during the COVID-19 pandemic.
    PLoS One. 2026;21:e0346851.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. ZHU Z, Fragkias M, Suh JW, McCoshan E, et al
    The Urban Pulse: Diagnosing the urbanization process as spiky, cyclical, and asynchronous.
    Proc Natl Acad Sci U S A. 2026;123:e2537770123.
    PubMed         Abstract available
    
    
21. SKELLY AN, Fan C, Keeffe JR, Okten AB, et al
    mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.
    Proc Natl Acad Sci U S A. 2026;123:e2536870123.
    PubMed         Abstract available
    
    

    
    Vaccine

22. WU X, Tao Y, Sun Y, Chen J, et al
    Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data.
    Vaccine. 2026;88:128782.
    PubMed         Abstract available
    
    
23. BIETZ A, Sandow P, Hartmann C, Steffan L, et al
    Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey.
    Vaccine. 2026;88:128765.
    PubMed         Abstract available
    
    
24. SONG L, He G, Cui Y, Tan R, et al
    Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines.
    Vaccine. 2026;87:128767.
    PubMed         Abstract available
    
    
25. FAIJUE DD, Bouaddi O, Segui AO, Morias B, et al
    Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis.
    Vaccine. 2026;85:128645.
    PubMed         Abstract available
    
    
26. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    PubMed         Abstract available
    
    
27. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    PubMed         Abstract available
    
    
28. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    PubMed         Abstract available
    
    
29. KOIRALA A, Prasad SA, Tjiam MC, Britton PN, et al
    SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.
    Vaccine. 2026;85:128705.
    PubMed         Abstract available
    
    
30. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    PubMed         Abstract available
    
    
31. DANCHIN M, Rak A, Vasiliadis S, Wang B, et al
    Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment.
    Vaccine. 2026;85:128710.
    PubMed         Abstract available
    
    
32. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    PubMed         Abstract available
    
    
33. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    PubMed         Abstract available
    
    
34. WANG R, Zhao Y, Yang J, Luo R, et al
    Systemic BCG administration induces transcription factor signature in CD4(+) T cells that cooperates with IL-12 signaling to drive antiviral Th1 differentiation.
    Vaccine. 2026;85:128720.
    PubMed         Abstract available
    
    

    
    Virology

35. KOVACS E, Rios Carrasco M, Guerreiro Cabana MF, de Vries RP, et al
    H5N1 2.3.4.4b HA E190D and Q226H mutations, picked up as minority variants in a patient, result in an inability to bind sialic acid.
    Virology. 2026;621:110949.
    PubMed         Abstract available
    
    

    
    Virus Res

36. TJARNHAGE E, Vatsveen TK, Raki M, Nemazee D, et al
    Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).
    Virus Res. 2026 Jun 9:199759. doi: 10.1016/j.virusres.2026.199759.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (AMEDEO, June 6 '26)

 

Ann Intern Med

1. KOUTOURATSAS T, Dammad T, Mylonakis E
   In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.
   Ann Intern Med. 2026 Jun 2. doi: 10.7326/ANNALS-26-01878.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. BONTEN M, Essink B, Hanning N, Leroux-Roels I, et al
   Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged >/=50 years: a phase 3, randomized, non-inferiority trial.
   Clin Infect Dis. 2026 Jun 4:ciag344. doi: 10.1093.
   PubMed         Abstract available
   
   
3. BRAMANTE CT, Stewart TG, Boulware DR, McCarthy MW, et al
   Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.
   Clin Infect Dis. 2026 Jun 4:ciag335. doi: 10.1093.
   PubMed         Abstract available
   
   
4. LIU C, Okoli GN, Chen R, Sullivan SG, et al
   SARS-CoV-2 vaccination and attenuation of breakthrough infection severity: A systematic global review and meta-analysis.
   Clin Infect Dis. 2026 Jun 1:ciag346. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

5. JURICA JM, Smith DM, Abeles S, Torriani FJ, et al
   Discontinuing contact precautions for COVID-19: the science says its time.
   Infect Control Hosp Epidemiol. 2026 Jun 5:1-3. doi: 10.1017/ice.2026.10482.
   PubMed         Abstract available
   
   
6. ALSOUBANI M, Andujar G, Campion M
   Socioeconomic and racial review of COVID-19 antiviral prescriptions: a large health system cohort.
   Infect Control Hosp Epidemiol. 2026 Jun 1:1-6. doi: 10.1017/ice.2026.10473.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

7. VEIJER C, van Asselt ADI, van Zon SKR, Rosmalen JGM, et al
   Healthcare Resource Use and Costs under Pandemic Circumstances in The Netherlands: Results from the Lifelines COVID-19 Cohort.
   Int J Infect Dis. 2026 Jun 3:108854. doi: 10.1016/j.ijid.2026.108854.
   PubMed         Abstract available
   
   
8. ABU-RADDAD LJ, Ayoub HH, Coyle P, Tang P, et al
   Routine SARS-CoV-2 Testing Frequency and Risk of Severe COVID-19: A Nationwide Population-Based Study.
   Int J Infect Dis. 2026 Jun 2:108851. doi: 10.1016/j.ijid.2026.108851.
   PubMed         Abstract available
   
   
9. LAW AHT, Wong JY, Lin Y, Cowling BJ, et al
   Sex differences in COVID-19 infection and mortality in Hong Kong.
   Int J Infect Dis. 2026 Jun 2:108852. doi: 10.1016/j.ijid.2026.108852.
   PubMed         Abstract available
   
   
10. LIN Y, Wu P, Lau EHY, Blais J, et al
    SARS-CoV-2 viral shedding and vaccination?modified effects of oral antivirals in older COVID-19 patients: a retrospective cohort study in Hong Kong.
    Int J Infect Dis. 2026 Jun 1:108848. doi: 10.1016/j.ijid.2026.108848.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. CHEN Y, Lan Y, Zhao A, Zhang Y, et al
    Anti-Zika Virus Activity of Azvudine via Inhibition of RNA Replication by Its Active Triphosphate Form.
    J Med Virol. 2026;98:e71000.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

12. XU X, Saad MB, Grippin A, Xu H, et al
    Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with Radiotherapy.
    J Thorac Oncol. 2026 Jun 1:103956. doi: 10.1016/j.jtho.2026.103956.
    PubMed         Abstract available
    
    

    
    J Virol

13. FAN L, Gao X, Feng W, Huang Q, et al
    SARS-CoV-2 ORF3a suppresses host antiviral interferon responses by promoting STUB1-mediated PTEN proteasomal degradation.
    J Virol. 2026 Jun 2:e0018626. doi: 10.1128/jvi.00186.
    PubMed         Abstract available
    
    

    
    Lancet

14. KARIM SA, Mahomed S, Lewis L, Karim SSA, et al
    Urgent need for a reliable rapid diagnostic test for the Ebola epidemic caused by Bundibugyo virus in Africa.
    Lancet. 2026 Jun 2:S0140-6736(26)01093-7. doi: 10.1016/S0140-6736(26)01093.
    PubMed        
    
    

    
    Lancet Infect Dis

15. 
    Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet Infect Dis. 2026 Jun 2:S1473-3099(26)00194.
    PubMed         Abstract available
    
    

    
    Science

16. EMANUEL N, Harrington E, Pallais A
    Home alone: Remote work, isolation, and mental health.
    Science. 2026;392:eaec7671.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 6 '26)

 

Arch Virol

1. PERDANA WY, Tsuneki-Tokunaga A, Rahmi KA, Hinay AA Jr, et al
   In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.
   Arch Virol. 2026;171:200.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. SHAO S, Dong ZY, Kang ZY, Zhang H, et al
   Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.
   Biochem Biophys Res Commun. 2026;825:153958.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

3. SANE J
   Rebuilding trust in public health: Beyond polarization.
   Epidemiol Infect. 2026;154:e71.
   PubMed         Abstract available
   
   
4. HASSELL K, Andrews N, Dabrera G, Kall M, et al
   Acute COVID-19 mortality in England in the omicron era: a national-level matched cohort study.
   Epidemiol Infect. 2026;154:e70.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. PRASERT K, Praphasiri P, Ditsungnoen D, Naosri S, et al
   Risk of hospitalization related to influenza A(H3N2) virus subclade K, Thailand, June-December 2025.
   J Infect Dis. 2026 May 31:jiag283. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Neurosurg Pediatr

6. ANDERSON MG, Pindrik J, Michelow IC, Anuar A, et al
   Pediatric sinogenic and otogenic intracranial infections requiring neurosurgical intervention: a North American multicenter study in the era of COVID-19.
   J Neurosurg Pediatr. 2026;37:621-631.
   PubMed         Abstract available
   
   

   
   J Virol

7. 
   CEIRR Risk Assessment Pipeline executive reports on H5N1 highly pathogenic avian influenza 2.3.4.4b, swine H1 1B.2, and H9N2 low pathogenicity avian influenza B4.7.2.
   J Virol. 2026 Jun 3:e0054526. doi: 10.1128/jvi.00545.
   PubMed         Abstract available
   
   
8. STEARNS K, Marcink T, Pawlack E, Sobolik EB, et al
   Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.
   J Virol. 2026 Jun 3:e0212625. doi: 10.1128/jvi.02126.
   PubMed         Abstract available
   
   
9. TURNER AH, Jaffrani SA, Kubinski HC, Ajayi DP, et al
   Rab11B is required for binding and entry of recent H3N2, but not H1N1, influenza A isolates.
   J Virol. 2026 Jun 2:e0211125. doi: 10.1128/jvi.02111.
   PubMed         Abstract available
   
   

   
   Pediatrics

10. ROSTAD CA, Healy CM, Nayak JL, Parameswaran L, et al
    Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.
    Pediatrics. 2026 May 4:e2025075223. doi: 10.1542/peds.2025-075223.
    PubMed         Abstract available
    
    

    
    PLoS One

11. EKWUNIFE O, Mangenah C, Ngwira L, Corbett E, et al
    Economic barriers to diagnostic equity: A multi-country analysis of patient costs for rapid SARS-CoV-2 testing in sub-Saharan Africa.
    PLoS One. 2026;21:e0350288.
    PubMed         Abstract available
    
    
12. HEMBERG M, Hansen AL, Storgaard J, Blay-Cadanet J, et al
    MAVS is important for antiviral defense against influenza A virus in a human respiratory epithelium model.
    PLoS One. 2026;21:e0350839.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

13. RIKANI A, Di Domenico L, Sabbatini CE, Navarro V, et al
    Resetting population mobility responses under repeated nonpharmaceutical interventions: Implications for hypothesized pandemic fatigue.
    Proc Natl Acad Sci U S A. 2026;123:e2533284123.
    PubMed         Abstract available
    
    
14. PAPADAKI M, Pavlos E, Dubourdeau M, Bailif V, et al
    Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.
    Proc Natl Acad Sci U S A. 2026;123:e2534726123.
    PubMed         Abstract available
    
    
15. GRUNDY JG, Pujols-Beltran M
    Bilingualism predicts executive function resilience after COVID-19 in aging.
    Proc Natl Acad Sci U S A. 2026;123:e2532470123.
    PubMed         Abstract available
    
    

    
    Vaccine

16. DE FIGUEIREDO A, Paterson P, Lin L, Mounier-Jack S, et al
    Changing socio-demographic determinants of seasonal influenza acceptance in England during the pandemic and a framework for predicting future acceptance.
    Vaccine. 2026;85:128629.
    PubMed         Abstract available
    
    
17. DAS S, Tenaglia BM, Riley D, Speed S, et al
    BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy.
    Vaccine. 2026;87:128774.
    PubMed         Abstract available
    
    

    
    Virus Res

18. SEDAGHAT M, Najafi F, Khosravi Shademani F, Rezaeian S, et al
    Seasonal influenza vaccine and frequency of adverse events in health workers receiving two doses of AstraZeneca vaccine: a retrospective cohort study.
    Virus Res. 2026;369:199757.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, May 30 '26)

 

Antiviral Res

1. MALOCCU S, Otsuka Y, Molchan E, Foti M, et al
   Identification of Nsp15 inhibitors restoring interferon-dependent antiviral activity against SARS-CoV-2.
   Antiviral Res. 2026;251:106443.
   PubMed         Abstract available
   
   

   
   BMJ

2. YAMEY G
   Trump and RFK Jr have a new approach to global health: holding vulnerable people to ransom.
   BMJ. 2026;393:e387444.
   PubMed        
   
   

   
   Graefes Arch Clin Exp Ophthalmol

3. XU X, Yu P, Wu S, Wang L, et al
   Repeatability of corneal diameter measured by Sirius versus IOLMaster 700 in myopic eyes: combined with consistency and relationship of sulcus-to-sulcus.
   Graefes Arch Clin Exp Ophthalmol. 2026 May 23. doi: 10.1007/s00417-026-07281.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

4. GIBAS KM, Head T, Broadley M, Mermel LA, et al
   Healthcare personnel masking: current practices and gaps in standardized thresholds.
   Infect Control Hosp Epidemiol. 2026 May 26:1-8. doi: 10.1017/ice.2026.10469.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. BRUNVOLL SH, Fagerland MW, Nygaard AB, Ellingjord-Dale M, et al
   Long COVID symptoms before and 3-35 Months after SARS-CoV-2 infection in a Norwegian prospective cohort study, symptoms over the pandemic and different virus variants.
   Int J Infect Dis. 2026 May 27:108822. doi: 10.1016/j.ijid.2026.108822.
   PubMed         Abstract available
   
   

   
   J Infect

6. LU L, Long Z, Chen F, Li Z, et al
   Global Disability-Adjusted Life Years Burden of Lower Respiratory Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.
   J Infect. 2026 May 25:106768. doi: 10.1016/j.jinf.2026.106768.
   PubMed         Abstract available
   
   
7. CORRAO G, Sguazzini E, Gori A, Monti E, et al
   All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
   J Infect. 2026;93:106769.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. 
   Correction to "Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants".
   J Med Virol. 2026;98:e70987.
   PubMed        
   
   
9. REPUSIC D, Korolija M, Livun A, Svagusa T, et al
   Multi-Layered Genomic and Clinical Analysis Identifies Novel Variants, Co-Occurring Single Nucleotide Polymorphism Pairs, and Clinical Determinants of Host-Pathogen Interaction in COVID-19 Severity.
   J Med Virol. 2026;98:e70984.
   PubMed         Abstract available
   
   

   
   Lancet

10. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
    Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
    Lancet. 2026;407:2195-2207.
    PubMed         Abstract available
    
    

    
    N Engl J Med

11. ZIMMERMANN WH, Ensminger S, Kutschka I, Paitazoglou C, et al
    Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.
    N Engl J Med. 2026;394:1991-2001.
    PubMed         Abstract available
    
    

    
    Nature

12. SUZUKI R, Yamasoba D, Kimura I, Wang L, et al
    Author Correction: Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
    Nature. 2026 May 29. doi: 10.1038/s41586-026-10665.
    PubMed        
    
    
13. ZENG AGX, Nagree MS, Jakobsen NA, Shah S, et al
    Human haematopoietic stem cells remember inflammatory stress.
    Nature. 2026 May 27. doi: 10.1038/s41586-026-10522.
    PubMed         Abstract available
    
    

    
    Radiology

14. SPOSATO A, Mazzola MA, Kunst MM
    Case 346: gamma-Aminobutyric Acid A Receptor Encephalitis.
    Radiology. 2026;319:e251976.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 30 '26)

 

Cell

1. DE SA KSG, Silva J, Bayarri-Olmos R, Baker CA, et al
   A causal link between autoantibodies and neurological symptoms in long COVID.
   Cell. 2026;189:3214-3235.
   PubMed         Abstract available
   
   
2. WALL EC, Richter AG
   Autoantibodies in long COVID: A mechanistic foothold in a heterogeneous disease.
   Cell. 2026;189:3179-3180.
   PubMed         Abstract available
   
   
3. FOURNIER M, Vanderkerken M, Dorgham K, Bastard P, et al
   Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
   Cell. 2026;189:3236-3253.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

4. KITAMURA N, Kondo N, Ith S, Okuyama M, et al
   Post-pandemic immunity debt for paediatric infectious diseases in Japan between 2014 and 2024.
   Epidemiol Infect. 2026;154:e67.
   PubMed         Abstract available
   
   

   
   J Immunol

5. WANG Q, McManus LR, Levine KS, Blanc R, et al
   A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.
   J Immunol. 2026;215:vkag106.
   PubMed         Abstract available
   
   

   
   J Infect

6. WEE LE, Ho RWL, Lim JT, Lim SK, et al
   Real-world effectiveness of influenza vaccination amongst children aged under 5 in a tropical setting.
   J Infect. 2026 May 26:106771. doi: 10.1016/j.jinf.2026.106771.
   PubMed         Abstract available
   
   
7. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
   A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
   J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
   PubMed         Abstract available
   
   
8. KIM HK, Jo S, Min KD, Cho SI, et al
   Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in Patients With Cancer: Evidence From a Nationwide Target Trial Emulation.
   J Infect. 2026 Apr 28:106753. doi: 10.1016/j.jinf.2026.106753.
   PubMed         Abstract available
   
   

   
   J Virol

9. LOES AN, Tarabi RAL, Li SH, Atkinson RK, et al
   Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.
   J Virol. 2026 May 27:e0031726. doi: 10.1128/jvi.00317.
   PubMed         Abstract available
   
   

   
   J Virol Methods

10. ZENG Q, Liu L, Wang T, Zhang C, et al
    Artificial intelligence-assisted technology to reduce turnaround time for rapid diagnosis of infectious diseases.
    J Virol Methods. 2026;344:115392.
    PubMed         Abstract available
    
    

    
    PLoS Biol

11. ZHOU F, Periasamy S, Jackson ND, Cheng WS, et al
    Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection.
    PLoS Biol. 2026;24:e3003808.
    PubMed         Abstract available
    
    

    
    PLoS Med

12. JANSEN E, Bockstal V, Herschke F, Olsson Gisleskog P, et al
    Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.
    PLoS Med. 2026;23:e1004609.
    PubMed         Abstract available
    
    

    
    PLoS One

13. SILVA-VALENCIA J, Tu K, Moineddin R, Butt DA, et al
    Trends in pulmonary exercise testing utilization after the COVID-19 pandemic in Ontario: A population-cohort study.
    PLoS One. 2026;21:e0349020.
    PubMed         Abstract available
    
    
14. WARNE DJ, Varghese A, Brewster A, Browning AP, et al
    Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours.
    PLoS One. 2026;21:e0349499.
    PubMed         Abstract available
    
    
15. AKIN HY, Tuncali T, Gencer EB, Cengiz Seval G, et al
    Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.
    PLoS One. 2026;21:e0345137.
    PubMed         Abstract available
    
    
16. SIROTIAK Z, Oberhauser AM, Sirotiak AM, Nettleton KA, et al
    Exploring the perceived impact of physical activity on physical and mental health among individuals with long COVID: A qualitative interview inquiry.
    PLoS One. 2026;21:e0350121.
    PubMed         Abstract available
    
    
17. FIORE E, Taio G, Morandi N, Mazzotta E, et al
    Lung ultrasonography to assess efficacy of intranasal and parenteral vaccinations for bovine respiratory disease (BRD) in dairy calves.
    PLoS One. 2026;21:e0349953.
    PubMed         Abstract available
    
    
18. AGYEI G, El-Duah P, Dumevi RM, Muzeniek T, et al
    Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.
    PLoS One. 2026;21:e0348281.
    PubMed         Abstract available
    
    
19. ROSSI SL, Cheng DM, Sereda Y, Truong V, et al
    COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis.
    PLoS One. 2026;21:e0349567.
    PubMed         Abstract available
    
    
20. YEO HY, Park JY, Marsh S, Castelino L, et al
    Evidence mapping of preference elicitation for non-pharmaceutical interventions targeting respiratory viral transmission: A scoping review protocol.
    PLoS One. 2026;21:e0344828.
    PubMed         Abstract available
    
    
21. KUBILIUTE I, Zaboras E, Majauskaite F, Urboniene J, et al
    Predicting severe COVID-19 disease in adults: A single-centre cohort study during the first three pandemic waves in 2020-2021 in Vilnius, Lithuania.
    PLoS One. 2026;21:e0350112.
    PubMed         Abstract available
    
    
22. BRIDGMAN WH, Safta C, Ray J
    A scalable variational method for estimating the latent infection-rate field of an outbreak.
    PLoS One. 2026;21:e0350090.
    PubMed         Abstract available
    
    
23. STOTZER E, Graner S, Sengpiel V, Wessberg A, et al
    Crisis leadership and strategic decisions in Swedish maternity care during the COVID-19 pandemic: A deductive analysis from the COPE staff project.
    PLoS One. 2026;21:e0346625.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. ADIGA A, Chopra A, Wilson ML, Ravi SS, et al
    A high-resolution, US-scale digital similar of interacting livestock, wild birds, and human ecosystems for multihost epidemic spread.
    Proc Natl Acad Sci U S A. 2026;123:e2507074123.
    PubMed         Abstract available
    
    

    
    Vaccine

25. JUFUKU R, Shinchi H, Murata K, Chan M, et al
    TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.
    Vaccine. 2026;86:128762.
    PubMed         Abstract available
    
    
26. LIU R, Fan Y, Xiong S, Lin J, et al
    Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.
    Vaccine. 2026;86:128761.
    PubMed         Abstract available
    
    
27. OKUBO Y, Honjyo R, Uda K, Miyairi I, et al
    Nationwide survey for household preparedness and vaccination acceptance during a novel influenza pandemic scenario in Japan, 2025.
    Vaccine. 2026;86:128738.
    PubMed         Abstract available
    
    
28. MYBURGH L, van Loon K, Koetsier J, Hansen Q, et al
    Conjugate vaccine technology enhances responses to influenza virus.
    Vaccine. 2026;86:128728.
    PubMed         Abstract available
    
    
29. HALFMANN PJ, Duffy A, Wang T, Kawaoka Y, et al
    Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters.
    Vaccine. 2026;84:128653.
    PubMed         Abstract available
    
    
30. LAMBERT D, Luisi N
    Prevalence and correlates of COVID-19 vaccine uptake among sexual and gender minority adolescents in the southern United States.
    Vaccine. 2026;84:128661.
    PubMed         Abstract available
    
    
31. SHEN Y, Shahn Z, Robertson MM, Gebo K, et al
    Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort.
    Vaccine. 2026;84:128666.
    PubMed         Abstract available
    
    
32. MULLER MP, Soe P, Shulha HP, Isenor JE, et al
    mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.
    Vaccine. 2026;84:128630.
    PubMed         Abstract available
    
    
33. AMOAKO N, Cohuet S, Adjei MR, Gurry C, et al
    COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
    Vaccine. 2026 Feb 17:128310. doi: 10.1016/j.vaccine.2026.128310.
    PubMed         Abstract available
    
    
34. BALAM S, Kane F, Traore B, Konate D, et al
    Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
    Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680.
    PubMed         Abstract available
    
    
35. GREY-JOHNSON M, Muhammad AK, Sillah F, Jones CJ, et al
    COVID-19 testing acceptance among symptomatic individuals screened for a randomized clinical trial in The Gambia.
    Vaccine. 2026;77 Suppl 1:127608.
    PubMed         Abstract available
    
    
36. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed         Abstract available
    
    
37. GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
    Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
    Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
    PubMed         Abstract available
    
    
38. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    PubMed         Abstract available
    
    
39. KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
    COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
    Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
    PubMed         Abstract available
    
    
40. ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
    Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
    Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
    PubMed         Abstract available
    
    
41. SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
    Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
    Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
    PubMed         Abstract available
    
    
42. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    PubMed         Abstract available
    
    
43. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed         Abstract available
    
    

    
    Virology

44. UNO N, Ross TM
    Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.
    Virology. 2026;621:110961.
    PubMed         Abstract available
    
    

    
    Virus Res

45. FARSIU N, Mahani FK, Arefinia N, Charostad J, et al
    From Legacy to Innovation: A Comprehensive Review of Vaccine Platforms Against Viral Infections.
    Virus Res. 2026 Apr 16:199730. doi: 10.1016/j.virusres.2026.199730.
    PubMed         Abstract available
    
    
46. VAN DIJK LLA, Rijsbergen LC, Havelaar AC, den Hartog Y, et al
    Innate airway responses shape permissiveness to human respiratory syncytial virus.
    Virus Res. 2026;368:199734.
    PubMed         Abstract available
    
    
47. JANGJOU A, Izadpanah P, Moqhadas M, Faramarzi H, et al
    QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study.
    Virus Res. 2026;368:199739.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, May 23 '26)

 

Am J Respir Crit Care Med

1. KRAMER L, Calfee CS, Mcauley DF, O'Kane C, et al
   Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.
   Am J Respir Crit Care Med. 2026 Apr 28:aamag213. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

2. MILLER M, Fischer S, Azrael D
   Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey.
   Ann Intern Med. 2026;179:637-644.
   PubMed         Abstract available
   
   

   
   Antiviral Res

3. LOISON S, Chabert M, Gensous C, Constant S, et al
   Cell-Type Specific Effects of SARS-CoV-2 P252L Mutation on Nirmatrelvir Sensitivity.
   Antiviral Res. 2026 May 19:106445. doi: 10.1016/j.antiviral.2026.106445.
   PubMed         Abstract available
   
   
4. PAGLIARI M, Lutken C, Vianello L, Mazzacan E, et al
   LTX-109 as a broad-spectrum antiviral: in vitro and in vivo efficacy against SARS-CoV-2 and Influenza Viruses.
   Antiviral Res. 2026 May 19:106444. doi: 10.1016/j.antiviral.2026.106444.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. ERIGUCHI Y, Shimono N
   Declining antibiotic consumption and changing sexually transmitted infection dynamics in Japan: a national ecological time-series analysis, 2013-2024.
   Int J Infect Dis. 2026 May 16:108804. doi: 10.1016/j.ijid.2026.108804.
   PubMed         Abstract available
   
   
6. MA Q, Yao L, Shang H, Han X, et al
   Reply to comment on SARS-CoV-2 variant-specific humoral immunity and long-term immune recovery in people living with HIV in the ancestral vaccine era.
   Int J Infect Dis. 2026 May 17:108812. doi: 10.1016/j.ijid.2026.108812.
   PubMed        
   
   
7. ABERA EG, Kisch R, Ali S, Tsegaye W, et al
   Dynamics and variant-specific patterns of SARS-CoV-2 reinfection in Ethiopia: a prospective longitudinal cohort study.
   Int J Infect Dis. 2026 May 18:108814. doi: 10.1016/j.ijid.2026.108814.
   PubMed         Abstract available
   
   

   
   J Infect

8. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
   A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
   J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
   PubMed         Abstract available
   
   
9. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
   Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
   J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
   PubMed         Abstract available
   
   

   
   J Med Virol

10. BU GL, Chen LN, Wu PH, Zeng MS, et al
    Preventing Both EBV Infection and EBV-Associated Diseases: Advances in Vaccine Research.
    J Med Virol. 2026;98:e70961.
    PubMed         Abstract available
    
    
11. FUKUDA Y, Fujii Y, Togashi A, Nawa T, et al
    Recent Increase in Rotavirus Gastroenteritis After Five Years of Low Activity in Hokkaido Prefecture, Japan, Associated With Equine-Like G3P[8] and G8P[8] Strains, 2025.
    J Med Virol. 2026;98:e70967.
    PubMed         Abstract available
    
    
12. SANSONE NMS, Costa PT, Mello LS, Marques LFA, et al
    Vaccination Coverage Against Coronavirus Disease 2019 (COVID-19) in Brazil's Indigenous Population.
    J Med Virol. 2026;98:e70965.
    PubMed         Abstract available
    
    
13. HORI M, Hayama-Terada M, Kitamura A, Hosozawa M, et al
    Prevalence and Risk Factors for Persistent Post-COVID-19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID-19 Study.
    J Med Virol. 2026;98:e70973.
    PubMed         Abstract available
    
    
14. YENOKYAN K, Wentz E, Ni Z, Kammerling T, et al
    Association of Comorbid and Incident Depression and Other Mental Health Conditions With Long-COVID: Results From the Johns Hopkins COVID Long Study.
    J Med Virol. 2026;98:e70970.
    PubMed         Abstract available
    
    

    
    J Virol

15. YAN P, Kyaw ZO, Wang X, Li N, et al
    Febrifugine dihydrochloride restricts porcine epidemic diarrhea virus replication by modulating the IGF1R-driven PI3K/AKT-apoptosis axis.
    J Virol. 2026;100:e0011726.
    PubMed         Abstract available
    
    
16. HUANG M, Liukang C, Yang H, Sun L, et al
    Infectious bronchitis virus accessory protein 3a induces renal inflammatory injury by activating the NLRP3 inflammasome via ER calcium mobilization and mitochondrial ROS production.
    J Virol. 2026;100:e0212525.
    PubMed         Abstract available
    
    
17. SCHIFFER JT, Reeves DB, Mayer B, Rodriguez LR, et al
    Clinical trial simulation of antiviral drugs.
    J Virol. 2026;100:e0181424.
    PubMed         Abstract available
    
    
18. SIVARAJAN R, Kirchgatterer PC, Lawrenz J, Tanner-Matiz E, et al
    Tonic and early interferons defend against respiratory viruses in primary human lung organoid-derived air-liquid interface cultures.
    J Virol. 2026 May 20:e0210425. doi: 10.1128/jvi.02104.
    PubMed         Abstract available
    
    

    
    Lancet

19. ISLAM MS, Chughtai AA, Wood JG, Sawleshwarkar S, et al
    Hantavirus outbreak on a cruise ship in the South Atlantic.
    Lancet. 2026 May 15:S0140-6736(26)00934-7. doi: 10.1016/S0140-6736(26)00934.
    PubMed        
    
    

    
    Nature

20. AYGUN E, Belyaeva A, Comanici G, Coram M, et al
    An AI system to help scientists write expert-level empirical software.
    Nature. 2026 May 19. doi: 10.1038/s41586-026-10658.
    PubMed         Abstract available
    
    
21. KOZLOV M
    Exclusive: NIH ousts infectious-disease leaders as COVID scientists face US charges.
    Nature. 2026 May 15. doi: 10.1038/d41586-026-01558.
    PubMed        
    
    

    
    Science

22. COHEN J
    Virologist accused of starting COVID-19 fights funding ban.
    Science. 2026;392:795-796.
    PubMed         Abstract available
    
    

    
    Travel Med Infect Dis

23. LI D, Tian F, Niu Y, Li H, et al
    Surveillance of Airborne Microorganisms and Associated Influencing Factors at an International Airport in China, 2019-2020.
    Travel Med Infect Dis. 2026 May 19:102992. doi: 10.1016/j.tmaid.2026.102992.
    PubMed         Abstract available
    
    
24. POLONI A, Rizzo A, Giacomelli A, Colaneri M, et al
    D-dimer as a marker of severe disease in imported malaria: a retrospective observational study.
    Travel Med Infect Dis. 2026;72:102994.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 23 '26)

 

Ann Intern Med

1. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
   Infectious Diseases: What You May Have Missed in 2025.
   Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
   PubMed         Abstract available
   
   
2. REIS G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, et al
   The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.
   Ann Intern Med. 2026 Mar 31. doi: 10.7326/ANNALS-25-03959.
   PubMed         Abstract available
   
   
3. MILLER M, Fischer S, Azrael D
   Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey.
   Ann Intern Med. 2026;179:637-644.
   PubMed         Abstract available
   
   
4. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
   Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05485.
   PubMed         Abstract available
   
   
5. MOSER ITK, Dobrescu AI, Sommer I, Goeschl S, et al
   Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05536.
   PubMed         Abstract available
   
   
6. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
   COVID-19 Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
   PubMed         Abstract available
   
   
7. DOBRESCU A, Pinte L, Sharifan A, Gadinger A, et al
   Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05044.
   PubMed         Abstract available
   
   

   
   Antiviral Res

8. PAGLIARI M, Lutken C, Vianello L, Mazzacan E, et al
   LTX-109 as a broad-spectrum antiviral: in vitro and in vivo efficacy against SARS-CoV-2 and Influenza Viruses.
   Antiviral Res. 2026 May 19:106444. doi: 10.1016/j.antiviral.2026.106444.
   PubMed         Abstract available
   
   
9. WANG W, Yang F, Liu K, Cai M, et al
   A mouse model of human-derived H10N3 influenza enables preclinical evaluation of antiviral efficacy.
   Antiviral Res. 2026 May 18:106436. doi: 10.1016/j.antiviral.2026.106436.
   PubMed         Abstract available
   
   

   
   J Gen Virol

10. SASVARI H, Sherry L, Logan N, Dunbar D, et al
    Serological response to feline coronavirus in the UK domestic cat population.
    J Gen Virol. 2026;107:002270.
    PubMed         Abstract available
    
    

    
    J Immunol

11. SAIDU A, Crawford JC, Walden S, Qu JH, et al
    Highly focused human CD8+ T-cell response in the lower airways during acute influenza infection.
    J Immunol. 2026;215:vkag068.
    PubMed         Abstract available
    
    

    
    J Infect

12. SMITH CS, Mohmand Z, Hrycyshyn A, Djerboua M, et al
    Risk of severe influenza in people with a history of injection drug use in Ontario: A population-based nested case control study.
    J Infect. 2026 May 20:106764. doi: 10.1016/j.jinf.2026.106764.
    PubMed         Abstract available
    
    

    
    J Virol

13. BAYUROVA E, Kostyushev D, Tikhonov A, Chulanov V, et al
    Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics.
    J Virol. 2026 Mar 23:e0007726. doi: 10.1128/jvi.00077.
    PubMed         Abstract available
    
    
14. POZHIDAEVA A, Hoch JC, Pustovalova Y
    The DMV pore-forming TM2-Y region of SARS-CoV-2 nsp3 exhibits structural conservation beyond the coronavirus family.
    J Virol. 2026 Apr 3:e0203825. doi: 10.1128/jvi.02038.
    PubMed         Abstract available
    
    
15. RAHEJA H, Sahu R, Ghosh T, Paul S, et al
    HuR enhances SARS-CoV-2 non-structural protein translation through the genomic 5'-UTR, by promoting polypyrimidine tract-binding protein binding.
    J Virol. 2026 Apr 16:e0027626. doi: 10.1128/jvi.00276.
    PubMed         Abstract available
    
    
16. SALISCH F, Muller-Ruttloff C
    Behind the membranous curtain-lipid dynamics and functions in coronaviral replication.
    J Virol. 2026 Apr 21:e0175325. doi: 10.1128/jvi.01753.
    PubMed         Abstract available
    
    
17. GUO D, Yu S, Ma K, Tao H, et al
    Concanavalin A targets phylogenetically conserved N-linked glycans on coronavirus spike proteins for broad-spectrum antiviral activity.
    J Virol. 2026 Apr 27:e0167925. doi: 10.1128/jvi.01679.
    PubMed         Abstract available
    
    
18. NASIR A, Lee D, Avena LE, Berrueta DM, et al
    Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.
    J Virol. 2026 Apr 27:e0022526. doi: 10.1128/jvi.00225.
    PubMed         Abstract available
    
    
19. CHEN L, Su H, Shang W, Nie T, et al
    SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.
    J Virol. 2026 Apr 27:e0222325. doi: 10.1128/jvi.02223.
    PubMed         Abstract available
    
    
20. KOTANI N, Iwasa K, Amimoto T, Yamashita C, et al
    Pseudovirus-mediated proximity labeling identifies candidate host cell membrane proteins involved in viral attachment.
    J Virol. 2026 Apr 29:e0050726. doi: 10.1128/jvi.00507.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

21. KLOCHKOV KA, Kozlov IE, Ilina EN, Manolov AI, et al
    Human mobility and outbreak origins in epidemic spread: Insights from agent-based modeling.
    PLoS Comput Biol. 2026;22:e1014279.
    PubMed         Abstract available
    
    

    
    PLoS One

22. EL KHATIB Y, Mukhamedova F
    An alternative strategy for balancing profit maximization and risk reduction.
    PLoS One. 2026;21:e0348577.
    PubMed         Abstract available
    
    
23. LINDAHL YL, Noren H, Engstrom AH, Grandahl M, et al
    A solo journey in the shadow of a double-edged pandemic: A qualitative study of women's experience of being pregnant during the COVID-19 pandemic.
    PLoS One. 2026;21:e0349378.
    PubMed         Abstract available
    
    
24. RAUT B, Palla G, Wang J, Campbell S, et al
    ThermiQuant AquaStream: A portable instrument for quantitative colorimetric isothermal nucleic acid amplification reactions in paper and tube formats.
    PLoS One. 2026;21:e0348607.
    PubMed         Abstract available
    
    
25. VISKUPIC F, Daly R, Wiltse DL, Gonda M, et al
    The relationship between personal COVID-19 vaccination decisions and cattle vaccination practices: Evidence from a survey of South Dakota beef producers.
    PLoS One. 2026;21:e0349234.
    PubMed         Abstract available
    
    
26. LENARZ AM, Park H, Roberts MT, Pan A, et al
    The impact of COVID-19 on longevity trends and disparities among Native Americans and Whites in the Four Corners States.
    PLoS One. 2026;21:e0347924.
    PubMed         Abstract available
    
    
27. WILLIAMS H, Armstrong M, Alexander R, Groner J, et al
    Dual pandemic of firearm injury and COVID-19 in Central and Southeastern Ohio: An interrupted time series analysis.
    PLoS One. 2026;21:e0335813.
    PubMed         Abstract available
    
    
28. GONGORA-BENDEZU JA, Martinez-Lopez MV, Aguinaga-Fernandez AD, Yovera-Aldana M, et al
    Post-COVID spirometric abnormalities in workers with intermittent high-altitude exposure: A cross-sectional study in Peru.
    PLoS One. 2026;21:e0329054.
    PubMed         Abstract available
    
    
29. RIOS MONTOYA V, Suarez Alarcon AY, Perez Castillo S, Zamudio Raez T, et al
    Beyond coverage: Can vaccination reduce child mortality despite structural inequality? A global ecological analysis of routine childhood immunization (2010-2023).
    PLoS One. 2026;21:e0340756.
    PubMed         Abstract available
    
    
30. KOO H, Morrow CD
    Shared autonomous HERV loci transcription identifies a unique circulating CD14+-xCR1+ mononuclear cell phenotype in a patient group with post-acute sequelae of COVID-19.
    PLoS One. 2026;21:e0349350.
    PubMed         Abstract available
    
    
31. SHOJI M, Nakaoka K, Ishikawa M, Kasai Y, et al
    Correction: Triethylamine inhibits influenza A virus infection and growth via mechanisms independent of viral neuraminidase and RNA-dependent RNA polymerase.
    PLoS One. 2026;21:e0349522.
    PubMed         Abstract available
    
    
32. LIN J, Chen J, Wan L, He W, et al
    Computational models for the classification of antibody specificity using heavy chain features.
    PLoS One. 2026;21:e0349143.
    PubMed         Abstract available
    
    
33. DENG Y, Tang Z, Chen Q, Hu X, et al
    Computational biology exposed a common pathogenic mechanism in influenza A and Guillain-Barre syndrome.
    PLoS One. 2026;21:e0349687.
    PubMed         Abstract available
    
    
34. ARINAITWE J, Bakamutumaho B, Mugenyi L, Kiwanuka N, et al
    The epidemiology of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus circulation among adult patients with acute respiratory illness in Kampala Metropolitan Area in Uganda.
    PLoS One. 2026;21:e0344869.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

35. 
    Correction for Corell-Escuin et al., Dermcidin has antiviral activity and protects against influenza.
    Proc Natl Acad Sci U S A. 2026;123:e2613956123.
    PubMed        
    
    
36. OZA AN, O'Brien KM, Gleeson JP
    Detecting changepoints in dynamical systems: Modeling time-varying transmission of seasonal influenza.
    Proc Natl Acad Sci U S A. 2026;123:e2533861123.
    PubMed         Abstract available
    
    

    
    Vaccine

37. TANG YS, Chen C, Lv H, Sun Y, et al
    Robust cross-neutralizing antibody responses but variable cellular immunity following either Comirnaty and Spikevax JN.1-adapted mRNA vaccination in the elderly.
    Vaccine. 2026;83:128634.
    PubMed         Abstract available
    
    
38. UKAH UV, Haapala JL, Benitez GV, DeSilva MB, et al
    Language and racial disparities in COVID-19 vaccination during pregnancy and lactation.
    Vaccine. 2026;83:128638.
    PubMed         Abstract available
    
    
39. PAUL KK, Torres M, Shih STF, Gray RT, et al
    Respiratory syncytial virus (RSV) vaccination program for older Australians reduces health inequalities: a distributional cost-effectiveness analysis.
    Vaccine. 2026;83:128644.
    PubMed         Abstract available
    
    
40. TUITE AR, Forbes N, Salvadori MI, Tunis M, et al
    Cost-effectiveness of ongoing COVID-19 vaccination in the context of high population immunity: A structured review of international economic evidence.
    Vaccine. 2026;83:128660.
    PubMed         Abstract available
    
    
41. HARMA V, Palsola M, Kuusipalo A, Lindh E, et al
    Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry.
    Vaccine. 2026;86:128736.
    PubMed         Abstract available
    
    
42. RANQUE B, Galtier F, Nunes H, Le Jeunne C, et al
    Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.
    Vaccine. 2026;86:128732.
    PubMed         Abstract available